- December 2025,Qurgen has completed a long-term (over 8 years) in vivo animal study from 2018 to 2026, in which 3 male and 2 female Cynomolgus monkeys have been given 12 repeated high doses of SON-DP transcription-factor treatment within 28 day period and went under 5 physical examinations in the last 8 years. No teratoma or tumor has since been found in these monkeys.
- Since the discovery of embryonic stem cells, their clinical application has long been hindered by an insurmountable challenge—in vivo tumorigenicity and localized teratoma formation. Our clinical data accumulated over eight years has shown no tumor occurrence, marking the first major breakthrough in the in vivo safety of stem cell therapeutics.
- This represents a critical breakthrough in the pharmaceutical development of transcription factor proteins.
- Starting with the three original innovative drugs, SON-DP, GHMT-DP and PMPN-DP, we have realized the serialized pharmaceutical development of transcription factors associated with 23,000 human genes. An era of artificially induced in vivo gene expression has officially begun.
- All drug designs adopt fully human-derived proteins, enabling the druggability to nearly reach 100% at the initial design stage. Featuring abundant valid targets, native human-derived properties and high clinical reliability.
- SON-DP drug design and its components contain no viral vectors, non-human RNA, non-human DNA or non-human proteins. All ingredients are fully defined, controllable, and safe. Recombinant proteins and adjuvants pose no risk of in vivo residual metabolism, gene modification or exogenous viral infection. The in vivo cellular reprogramming cycle lasts 4 to 5 days, with a short metabolic and excretion cycle of 3 to 5 days. The therapeutic effect ceases immediately after drug discontinuation, ensuring outstanding safety and stability.
